Study Confirms Efficacy of Sutent® for Initial Treatment of Metastatic Kidney Cancer

Posted on March 8th, 2009 by

</p> <p>Study Confirms Efficacy of Sutent® for Initial Treatment of Metastatic Kidney Cancer</p> <p>

According to updated results from a Phase III clinical trial, initial treatment of metastatic kidney cancer with Sutent® (sunitinib) results in significantly better response rates and progression-free survival than treatment with interferon alfa. These results were presented at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO).

The kidneys are each filled with tiny tubules that clean and filter the blood; this process removes waste and makes urine. Renal cell cancer (RCC) is a malignancy involving these tubules of the kidney. Metastatic RCC refers to cancer that has spread from the kidney to distant sites in the body. Metastatic RCC was historically treated with interferon alfa, an agent that stimulates the immune system to help fight the cancer.

Sutent is an oral targeted agent that works by inhibiting multiple biologic pathways involved in the growth, replication, and spread of cancer cells. Sutent deprives cancer cells of blood and nutrients needed for growth.

To compare Sutent to interferon in the initial treatment of metastatic RCC, researchers conducted a Phase III clinical trial among 750 patients. Patients were assigned to receive either Sutent or interferon.

Initial results from this study, published in 2007, indicated that patients treated with Sutent experienced significantly longer progression-free survival than patients treated with interferon.[1] At the 2008 ASCO meeting, researchers provided updated results from this study;[2] these updated results confirmed the benefits of Sutent that were reported previously:

  • Progression-free survival was 11 months among patients treated with Sutent compared with five months among patients treated with interferon.
  • Anticancer responses occurred in 47% of patients treated with Sutent compared with 12% of patients treated with interferon.
  • Overall survival was 26.4 months among patients treated with Sutent compared with 21.8 months among patients treated with interferon. This result did not meet the criteria for statistical significance, which means that it could have occurred by chance alone.
  • The most common serious (grade 3 or 4) adverse events among patients treated with Sutent were high blood pressure, fatigue, diarrhea, and hand-foot syndrome. The most common serious adverse events among patients treated with interferon were fatigue and loss of appetite.

These results provide additional evidence that Sutent improves outcomes among patients with metastatic kidney cancer.

References:


[1] Motzer R, Hutson T, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine. 2007; 356:115-124.

[2] Figlin RA, Hutson TE, Tomczak P et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). Proceedings from the 44th annual meeting of the American Society of Clinical Oncology. Chicago, IL. 2008. Abstract #5024.

Related News: Sutent® Improves Progression-free Survival over Interferon in Kidney Cancer (1/11/2007)

Copyright Renal Cancer Information Center on CancerConsultants.com

Copyright © 2010 CancerConsultants. All Rights Reserved.

Tags: Uncategorized

You must be logged-in to the site to post a comment.